Wuxi XDC<2268 placing of new shares

Wuxi XDC<2268 placing of new shares

WuXi XDC Cayman Inc. (2268.HK), a leading contract research, development, and manufacturing organization, has announced a new share placement. The company, based in Wuxi, China, operates globally and specializes in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. Additionally, WuXi XDC provides international sales contracting services.

The share placement details include the issuance of new shares, though specific financial details such as the amount raised and the price per share are not provided in the available source materials. The announcement underscores WuXi XDC's strategic efforts to bolster its R&D capabilities and expand its global presence.

WuXi XDC has been actively involved in the biopharmaceutical sector since its inception in 2013. It operates as a subsidiary of WuXi Biologics (Cayman) Inc. and is known for its expertise in antibody drug conjugates, a key area in biopharmaceutical research. The company's focus on advanced manufacturing and R&D services positions it as a critical player in the global biotech market.

The new share placement is part of WuXi XDC's ongoing strategy to enhance its operational efficiency and expand its product portfolio. This move aligns with the company's mission to deliver innovative solutions to the biopharmaceutical industry. While specific financial implications and market reactions are not detailed in the provided materials, the announcement signals a commitment to growth and innovation.

For investors and financial professionals, the new share placement represents an opportunity to participate in the growth of a leading biotech company. The company's strategic positioning and global footprint make it a significant player in the competitive biopharmaceutical sector.

References:
[1] WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. [https://www.wuxixdc.com](https://www.wuxixdc.com)